Verici Dx PLC on Monday said that pricing had been finalised for two of its pre- and post-transplant tests, in line with the group’s strategy to ‘develop and commercialise a complementary suite of ground-breaking products’.
Verici is a Cardiff, Wales-based company, which develops advanced clinical diagnostics for organ transplants.
In May, a median rate of $2,650 was proposed for Verici’s Tutivia blood test by the Centers for Medicare & Medicaid Services, a federal agency within the US Department of Health.
In December, data from trials of Tutivia showed that it delivered a ‘significant improvement’ in biomarker offerings for post-transplant blood tests.
The CMMS has now finalised a clinical laboratory fee schedule rate at this proposed amount for the Tutivia post-transplant test and the Clarava pre-transplant prognosis test. This rate became effective on Monday, January 1.
Pricing for the two tests, which provide prognoses and estimates of rejection for patients undergoing kidney transplants, was established through a ‘gapfill’ process, used by CMMS to establish rates for laboratory tests where no similar tests have been priced.
The group said that having a rate established by the CMMS ‘represents a step toward securing reimbursement for testing by Medicare’, which covers around 63.9 million patients in the US.
Verici Chief Executive Officer Sara Barrington said: ‘This is another important milestone in our strategy to develop and commercialise a complementary suite of ground-breaking products that offer end-to-end testing for kidney transplant patients and their clinicians’.
The group also confirmed that the College of American Pathology had accredited its testing laboratory in Franklin, Tennessee, following the completion of an on-site audit. The group said that it had requested the accreditation ‘as part of its ongoing commitment to maintaining best in class quality systems’.
Shares in Verici were up 9.4% at 11.38 pence each in London on Monday morning.
Copyright 2024 Alliance News Ltd. All Rights Reserved.
